Protocols and cycles
Start from a goal for side-by-side comparisons and worked-out example protocols, or scan every compound’s dose, frequency and 26-week cycle below.
Guides by goal
Each guide compares the options for one goal, with evidence labels, example protocols with syringe draws already worked out, practical tips and safety notes.
Weight loss
The approved GLP-1 drugs, the newer investigational ones, and fat-loss peptides with far less evidence.
Injury recovery
BPC-157, TB-500 and their blends, plus peptides aimed at joints, the gut and nerves.
Growth hormone support
GHRH analogs, ghrelin-receptor agonists, tesamorelin and IGF-1 LR3.
Skin, hair and tanning
Copper peptides, a cosmetic peptide and the two melanotans.
Focus, mood and sleep
Selank, Semax, their blend, Adamax, Pinealon, DSIP and Cerebrolysin.
Energy and longevity
NAD+, MOTS-c, SS-31, glutathione and the bioregulator courses.
Sexual health and fertility
PT-141, hCG, kisspeptin-10 and oxytocin.
Immune and gut
Thymosin alpha-1, Thymalin, KPV and VIP.
Tools and basics
The calculator and the other tools, plus the basics of mixing, injecting and reading a lab report.
Dosage calculator
Vial, water and dose in; syringe units out.
OpenCompare peptides
Up to three side by side.
OpenStack check
Documented overlaps and one tracking checklist.
OpenDose log
Vials, doses and site rotation, kept on this device.
OpenReconstitution guide
How much water to add and how to mix.
OpenInjection guide
Sites, rotation, technique and sharps.
OpenStart here
How the site and its evidence tags work.
OpenReading a lab report
What a peptide COA should show.
OpenGlossary
Plain definitions of the terms used here.
OpenEvery compound by cycle pattern
Pick a pattern to filter the table.
| Compound | Evidence | Common dose | Frequency | Cycle, first 26 weeks |
|---|---|---|---|---|
| Weight & metabolic | ||||
| SemaglutideGLP-1 receptor agonist | Approved drug | 0.25 → 2.4 mg weekly | Once weekly | Continuous |
| TirzepatideDual GIP / GLP-1 receptor agonist | Approved drug | 2.5 → 15 mg weekly | Once weekly | Continuous |
| RetatrutideGIP / GLP-1 / glucagon triple agonist | Human studies | 2 → 12 mg weekly | Once weekly | Continuous |
| CagrilintideLong-acting amylin analog | Human studies | 0.25 → 2.4 mg weekly | Once weekly | Continuous |
| AOD9604Modified growth hormone fragment | Human studies | 300 mcg daily | Once daily | 12 weeks on, 4 off |
| 5-Amino-1MQNNMT inhibitor (small molecule) | Preclinical | No set injectable dose | Once daily | 8 weeks on, 4 off |
| SLU-PP-332Estrogen-related receptor agonist (small molecule) | Preclinical | 500 mcg–1 mg daily | 1–2× daily | 8 weeks on, 4 off |
| L-CarnitineFatty-acid transport cofactor | Approved drug | 500 mg IM, 3× weekly | Daily or 3× per week | 12 weeks on, 4 off |
| Mitochondria & longevity | ||||
| NAD+Coenzyme | Human studies | 50–100 mg, 2–3× weekly | 2–3× per week | No set cycle |
| MOTS-cMitochondrial-derived peptide | Preclinical | 5 mg, 1–3× weekly | 1–3× per week | 8 weeks on, 4 off |
| SS-31Mitochondria-targeted peptide | Approved drug | Label 40 mg; community 1–10 mg daily | Once daily | 8 weeks on, 4 off |
| GlutathioneAntioxidant tripeptide | Approved drug | 200–600 mg, 2–3× weekly | 2–3× per week | No set cycle |
| EpithalonPineal bioregulator peptide | Preclinical | 5–10 mg daily for 10–20 days | Once daily during a course | 2-week course, about every 5 months |
| Recovery & repair | ||||
| BPC-157Tissue-repair peptide | Preclinical | 250–500 mcg, 1–2× daily | 1–2× daily | 6 weeks on, 3 off |
| TB-500Tissue-repair peptide | Preclinical | 2–2.5 mg twice weekly, then weekly | 2× per week, then weekly | Load 5 weeks, maintain 6, then 6 off |
| BPC-157 + TB-500Repair blend | Blend | 250–500 mcg of each, daily | Once daily | 6 weeks on, 3 off |
| GLOW blendSkin and repair blend | Blend | 1–2 mg GHK-Cu share, daily | Once daily | 6 weeks on, 3 off |
| KLOW blendSkin, repair and anti-inflammatory blend | Blend | 1–2 mg GHK-Cu share, daily | Once daily | 6 weeks on, 3 off |
| KPVAnti-inflammatory peptide | Preclinical | 200–500 mcg daily | Once daily | 8 weeks on, 8 off |
| ARA-290Tissue-protective peptide (EPO-derived) | Human studies | 4 mg daily for 28 days | Once daily | One 4-week course |
| CartalaxShort bioregulator peptide | Preclinical | ~200 mcg daily for 10–20 days | Once daily during a course | 2-week course, about every 4 months |
| Growth hormone axis | ||||
| CJC-1295 (no DAC)GHRH analog | Preclinical | 100 mcg, 1–3× daily | 1–3× daily (bedtime most common) | 12 weeks on, 4 off |
| CJC-1295 with DACLong-acting GHRH analog | Human studies | 1 mg weekly | Once weekly | 12 weeks on, 4 off |
| CJC-1295 + IpamorelinGH secretagogue blend | Blend | 100 mcg of each, nightly | Once nightly | 12 weeks on, 4 off |
| IpamorelinGhrelin-receptor agonist (GHRP) | Human studies | 100–300 mcg, 1–3× daily | 1–3× daily (bedtime most common) | 12 weeks on, 4 off |
| SermorelinGHRH analog | Human studies | 200–300 mcg nightly | Once nightly | No set cycle |
| TesamorelinGHRH analog | Approved drug | 1–2 mg daily | Once daily | Continuous |
| Tesamorelin + IpamorelinGH secretagogue blend | Blend | 1 mg tesamorelin share, nightly | Once daily | 12 weeks on, 4 off |
| IGF-1 LR3IGF-1 analog | Preclinical | 20–50 mcg daily | Once daily | 4 weeks on, 4 off |
| Skin, hair & tanning | ||||
| GHK-CuCopper peptide | Human studies | 1–2 mg daily | Once daily | 6 weeks on, 3 off |
| AHK-CuCopper peptide (hair and skin) | Preclinical | Topical 0.01–0.2% serum | Once daily (topical) | Continuous |
| SNAP-8Cosmetic anti-wrinkle peptide | Human studies | Topical 15–50 ppm | Twice daily (topical) | Continuous |
| Melanotan 1Melanocortin agonist (tanning) | Approved drug | 0.25 → 1 mg daily, then 2–3× weekly | Daily while loading, then 2–3× per week | Load 3 weeks, then maintain |
| Melanotan 2Melanocortin agonist (tanning) | Human studies | 250–500 mcg daily, then weekly | Daily while loading, then 1–2× per week | Load 4 weeks, then maintain |
| Hormones & sexual health | ||||
| hCGGonadotropin (LH-receptor agonist) | Approved drug | 250–500 IU every other day (with TRT) | Every other day (with TRT) | Continuous |
| Kisspeptin-10Reproductive-axis stimulator | Human studies | 100 mcg daily | Once daily | 6 weeks on, 4 off |
| PT-141Melanocortin-receptor agonist | Approved drug | 1.75 mg as needed | As needed (max 8 a month) | As needed |
| OxytocinPeptide hormone | Approved drug | 20–24 IU intranasal, as needed | As needed | As needed |
| Cognition & sleep | ||||
| SelankAnxiolytic peptide (tuftsin analog) | Approved drug | ~300 mcg, 1–3× daily | 1–3× daily | 2 weeks on, 2 off |
| SemaxNootropic peptide (ACTH fragment analog) | Approved drug | 200–300 mcg, 2–4× daily | 2–4× daily | 2 weeks on, 1 off |
| Selank + SemaxNootropic blend | Blend | 300 mcg of each, 1–2× daily | 1–2× daily | 2 weeks on, 2 off |
| AdamaxExperimental Semax-derived peptide | Preclinical | ~300 mcg daily | Once daily | No set cycle |
| DSIPSleep and stress neuropeptide | Approved drug | 100–300 mcg before bed | Once nightly | 2 weeks on, 2 off |
| CerebrolysinNeurotrophic peptide preparation | Approved drug | No protocol for research vials | Once daily during a course | 4-week course, about every 4 months |
| PinealonShort bioregulator peptide | Preclinical | ~1 mg daily for 10–20 days | Once daily during a course | 2-week course, about every 6 months |
| Immune | ||||
| Thymosin Alpha-1Immune modulator | Approved drug | 1.6 mg twice weekly | Twice weekly | Continuous |
| ThymalinImmune modulator (thymic extract) | Approved drug | 5–20 mg daily for 3–10 days | Once daily during a course | 1-week course, about every 4 months |
| VIPNeuropeptide | Human studies | 50 mcg nasal, 4× daily | 4× daily (nasal) | Continuous |